SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-23
👔
Outlook Therapeutics, Inc.
@OTLK_InsiderForm 4 Filing: KENYON LAWRENCE A Acquires (Grant) shares of $OTLK
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
Outlook Therapeutics, Inc.
Ticker: $OTLK
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-21
Shares: 210,078
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, KENYON LAWRENCE A, holds the title of Chief Financial Officer at Outlook Therapeutics, Inc..
On 2026-07-21, the insider transacted 210,078 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
KENYON LAWRENCE A (Chief Financial Officer) was granted $0 of $OTLK
Post-Transaction Position: 210,078 shares
SEC Accession No: 0001649989-26-000007 (CIK: 1230484)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.